Alan Brochstein

Anika Therapeutics Should Rise on European Approval

In reviewing your posts, I agree with a lot of your points. I would point out, however, that Elevess will compete with Restylane (MRX) and Juvederm (AGN), not Botox. They are complementary products that work for different types of facial wrinkles. I also think, unfortunately, that one can't extrapolate the success of Orthovisc to Elevess, as it is a totally different "market" (ortho vs derma/cosmetic). I posted the following to another poster:

I started a position this morning, having been watching for a while. They reported a pretty disappointing quarter, but no sellers emerged. Not a surprising reaction, given that the launch of Elevess is imminent.

I am buying for the following reasons: Orthovisc and Elevess cater to high growth markets, the stock is very reasonably priced in terms of PE, P/B and P/S, it is virtually uncovered by Wall Street and it has a stellar balance sheet. I am willing to ride the coattails of Royce, and there are some other smart guys too (DFA). I see this as a value stock today and a growth stock tomorrow (well, later this year!).

My concerns: Not sure about management (due to my lack of knowledge only), not sure about competitive landscape. Galderma is a great partner, but AGN and MRX are marketing machines.

I am not betting the ranch at 13.45, but there should be enough upside to get more exposure later after the launch happens. If this stock can get a 25 multiple on 2008 EPS, it is headed to 19 (or higher if the earnings come in ahead of projections).

Anika Therapeutics Receives FDA Approval for Cosmetic Tissue Enhacement Product

I started a position this morning, having been watching for a while. They reported a pretty disappointing quarter, but no sellers emerged. Not a surprising reaction, given that the launch of Elevess is imminent.

I am buying for the following reasons: Orthovisc and Elevess cater to high growth markets, the stock is very reasonably priced in terms of PE, P/B and P/S, it is virtually uncovered by Wall Street and it has a stellar balance sheet. I am willing to ride the coattails of Royce, and there are some other smart guys too (DFA). I see this as a value stock today and a growth stock tomorrow (well, later this year!).

My concerns: Not sure about management (due to my lack of knowledge only), not sure about competitive landscape. Galderma is a great partner, but AGN and MRX are marketing machines.

I am not betting the ranch at 13.45, but there should be enough upside to get more exposure later after the launch happens. If this stock can get a 25 multiple on 2008 EPS, it is headed to 19 (or higher if the earnings come in ahead of projections).